Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 275029, 10 pages
http://dx.doi.org/10.1155/2015/275029
Clinical Study

Effectiveness of the First Dose of BCG against Tuberculosis among HIV-Infected, Predominantly Immunodeficient Children

1Departamento de Pediatria, Universidade Agostinho Neto, Avenida Amilcar Cabral, s/n, Maianga, Luanda, Angola
2Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
3Departamento de Medicina Tropical, Universidade Federal de Pernambuco, Avenida Professor Moraes Rêgo, s/n, Bloco A do Hospital das Clínicas, Cidade Universitária, 50670-420 Recife, PE, Brazil
4Pós-Graduação em Medicina Tropical, Universidade Federal de Pernambuco, Avenida Professor Moraes Rêgo, s/n, Bloco A do Hospital das Clínicas, Cidade Universitária, 50670-420 Recife, PE, Brazil
5Departamento de Saúde Coletiva, CPqAM, FIOCRUZ, Avenida Professor Moraes Rêgo, s/n, Campus da UFPE, Cidade Universitária, 50670-420 Recife, PE, Brazil
6Programa de Mestrado e Doutorado em Ciências da Saúde, UPE, Rua Arnóbio Marques, No. 310, Santo Amaro, 50100-130 Recife, PE, Brazil

Received 25 February 2015; Accepted 19 May 2015

Academic Editor: Pere Domingo

Copyright © 2015 Joaquim C. V. D. Van-Dunem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, The Burden of Disease Caused by TB. Global Tuberculosis Report 2013, World Health Organization, Geneva, Switzerland, 2013.
  2. WHO, Tuberculosis country profile, 2013, http://www.who.int/tb/country/data/profiles/en/.
  3. UNIAIDS, HIV and AIDS estimates, 2013, http://www.unaids.org/en/regionscountries/countries/angola.
  4. P. E. M. Fine, “Bacille Calmette-Guérin vaccines: a rough guide,” Clinical Infectious Diseases, vol. 20, no. 1, pp. 11–14, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. G. A. Colditz, C. S. Berkey, F. Mosteller et al., “The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature,” Pediatrics, vol. 96, no. 1, pp. 29–35, 1995. View at Google Scholar · View at Scopus
  6. L. C. Rodrigues, V. K. Diwan, and J. G. Wheeler, “Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis,” International Journal of Epidemiology, vol. 22, no. 6, pp. 1154–1158, 1993. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Behr, “BCG—different strains, different vaccines?” Lancet Infectious Diseases, vol. 2, no. 2, pp. 86–92, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. Behr, M. A. Wilson, W. P. Gill et al., “Comparative genomics of BCG vaccines by whole-genome DNA microarray,” Science, vol. 284, no. 5419, pp. 1520–1523, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. D. S. Kernodle, “Decrease in the effectiveness of bacille Calmette-Guérin vaccine against pulmonary tuberculosis: a consequence of increased immune suppression by microbial antioxidants, not overattenuation,” Clinical Infectious Diseases, vol. 51, no. 2, pp. 177–184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Mangtani, I. Abubakar, C. Ariti et al., “Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials,” Clinical Infectious Diseases, vol. 58, no. 4, pp. 470–480, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Besnard, S. Sauvion, C. Offredo et al., “Bacillus Calmette-Guerin infection after vaccination of human immunodeficiency virus-infected children,” Pediatric Infectious Disease Journal, vol. 12, no. 12, pp. 993–997, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. K. L. O'Brien, A. J. Ruff, M. A. Louis et al., “Bacillus Calmette-Guérin complications in children born to HIV-1-infected women with a review of the literature,” Pediatrics, vol. 95, no. 3, pp. 414–418, 1995. View at Google Scholar · View at Scopus
  13. K. M. Edwards and D. S. Kernodle, “Possible hazards of routine Bacillus calmette-guerin immunization in human immunodeficiency virus-infected children,” The Pediatric Infectious Disease Journal, vol. 15, no. 9, pp. 836–838, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. A. C. Hesseling, H. S. Schaaf, W. A. Hanekom et al., “Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children,” Clinical Infectious Diseases, vol. 37, no. 9, pp. 1226–1233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. C. Hesseling, H. Rabie, B. J. Marais et al., “Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-unifected children,” Clinical Infectious Diseases, vol. 42, no. 4, pp. 548–558, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. World Health Organization, “BCG vaccine,” The Weekly Epidemiological Record, vol. 79, pp. 27–40, 2004. View at Google Scholar
  17. World Health Organization, “Revised BCG vaccination guidelines for infants at risk for HIV infection,” Weekly Epidemiological Record, vol. 82, pp. 181–196, 2007. View at Google Scholar
  18. W. J. Moss, C. J. Clements, N. A. Halsey, and W. H. Feinstone, “Immunization of children at risk of infection with human immunodeficiency virus,” Bulletin of the World Health Organization, vol. 81, no. 1, pp. 61–70, 2003. View at Google Scholar · View at Scopus
  19. J. J. C. Nuttal and B. S. Eley, “BCG vaccination in HIV-infected children,” Tuberculosis Research and Treatment, vol. 2011, Article ID 712736, 6 pages, 2011. View at Publisher · View at Google Scholar
  20. UNICEF, The State of the World's Children 2004: Girls, Education and Development, UNICEF, New York, NY, USA, 2004.
  21. World Health Organization, Provisional Guidelines for the Diagnosis and Classification of the Target Diseases for Primary Health Care, Surveillance and Special Studies, World Health Organization, Geneva, Switzerland, 1983.
  22. J. Van-Dunem, C. A. Fernandes, D. Ferraz et al., “Avaliação laboratorial do desempenho de diferentes testes rápidos e simples para detecção de anticorpos contra VIH-1/VIH-2 em Angola,” Acta Médica Angolana, vol. 142, pp. 87–97, 2004. View at Google Scholar
  23. P. E. M. Fine, “BCG vaccination against tuberculosis and leprosy,” British Medical Bulletin, vol. 44, no. 3, pp. 691–703, 1988. View at Google Scholar · View at Scopus
  24. P. G. Smith, “Epidemiological methods to evaluate vaccine efficacy,” British Medical Bulletin, vol. 44, no. 3, pp. 679–690, 1988. View at Google Scholar · View at Scopus
  25. G. J. Bhat, V. K. Diwan, C. Chintu, M. Kabika, and J. Masona, “HIV, BCG and TB in children: a case control study in Lusaka, Zambia,” Journal of Tropical Pediatrics, vol. 39, no. 4, pp. 219–223, 1993. View at Publisher · View at Google Scholar · View at Scopus
  26. M. P. Arbeláez, K. E. Nelson, and A. Muñoz, “BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection,” International Journal of Epidemiology, vol. 29, no. 6, pp. 1085–1091, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Allen, J. Batungwanayo, K. Kerlikowske et al., “Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women,” American Review of Respiratory Disease, vol. 146, no. 6, pp. 1439–1444, 1992. View at Publisher · View at Google Scholar · View at Scopus
  28. G. V. Baily, “Tuberculosis prevention trial, Madras,” Indian Journal of Medical Research, vol. 72, pp. S1–S74, 1980. View at Google Scholar
  29. G. W. Comstock and C. E. Palmer, “Long-term results of BCG vaccination in the southern United States,” American Review of Respiratory Disease, vol. 93, no. 2, pp. 171–183, 1966. View at Google Scholar · View at Scopus
  30. H. M. Curtis, I. Leck, and F. N. Bamford, “Incidence of childhood tuberculosis after neonatal BCG vaccination,” The Lancet, vol. 1, no. 8369, pp. 145–148, 1984. View at Google Scholar · View at Scopus
  31. P. D. Hart and I. Sutherland, “BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life,” British Medical Journal, vol. 2, no. 6082, pp. 293–295, 1977. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Abubakar, L. Pimpin, C. Ariti et al., “Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis,” Health Technology Assessment, vol. 17, no. 37, pp. 1–4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Smith, E. Wiegeshaus, and V. Balasubramanian, “An analysis of some hypotheses related to the Chingelput Bacille Calmette-Guérin trial,” Clinical Infectious Diseases, vol. 31, no. 3, pp. S77–S80, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. P. E. M. Fine, “Variation in protection by BCG: implications of and for heterologous immunity,” The Lancet, vol. 346, no. 8986, pp. 1339–1345, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. C. E. Palmer and M. W. Long, “Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis,” The American Review of Respiratory Disease, vol. 94, no. 4, pp. 553–568, 1966. View at Google Scholar · View at Scopus
  36. G. A. Colditz, T. F. Brewer, C. S. Berkey et al., “The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature,” The Journal of the American Medical Association, vol. 271, no. 9, pp. 698–702, 1994. View at Google Scholar
  37. M. E. Wilson, H. V. Fineberg, and G. A. Colditz, “Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine,” Clinical Infectious Diseases, vol. 20, no. 4, pp. 982–991, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. P. G. Smith, “Retrospective assessment of the effectiveness of BCG vaccination against tuberculosis using the case-control method,” Tubercle, vol. 63, no. 1, pp. 23–35, 1982. View at Publisher · View at Google Scholar · View at Scopus
  39. P. E. M. Fine, J. M. Ponnighaus, and N. Maine, “The distribution and implications of BCG scars in northern Malawi,” Bulletin of the World Health Organization, vol. 67, no. 1, pp. 35–42, 1989. View at Google Scholar · View at Scopus
  40. N. Sivarajah, S. Sivayogan, J. Jegatheesan, and V. Gnananathan, “BCG vaccination and development of a scar,” The Ceylon Mmedical Journal, vol. 35, no. 2, pp. 75–77, 1990. View at Google Scholar · View at Scopus
  41. I. Ildirim, N. Sapan, and B. Çavusoglu, “Comparison of BCG vaccination at birth and at third month of life,” Archives of Disease in Childhood, vol. 67, no. 1, pp. 80–82, 1992. View at Publisher · View at Google Scholar · View at Scopus
  42. J. W. Fang, B. M. Ko, and J. A. Wilson, “BCG vaccination scars: incidence and acceptance amongst British high-school children,” Child: Care, Health and Development, vol. 19, no. 1, pp. 37–43, 1993. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Pyakalia and R. Pust, “B.C.G. scar surveys in Enga province: a medical anthropology note,” Papua and New Guinea Medical Journal, vol. 20, no. 3, pp. 141–142, 1977. View at Google Scholar · View at Scopus
  44. R. Beskow, M. Bleiker, G. Dahlstrom, T. Mellbin, I. Sjogren, and K. Styblo, “Sensitivity to tuberculin in Swedish schoolboys vaccinated with BCG at birth,” Bulletin of the International Union against Tuberculosis, vol. 55, no. 3-4, pp. 101–106, 1980. View at Google Scholar · View at Scopus
  45. G. V. Baily, “Tuberculosis prevention Trial, Madras,” Indian Journal of Medical Research, vol. 72, pp. S1–S74, 1980. View at Google Scholar · View at Scopus
  46. J. C. V. D. van-Dunem, L. C. A. de Alencar, L. C. Rodrigues, M. D. F. P. M. D. Albuquerque, M. E. Ramos, and R. A. D. A. Ximenes, “Sensitivity and specificity of BCG scar reading among HIV-infected children,” Vaccine, vol. 28, no. 9, pp. 2067–2069, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. S. M. Pereira, I. Dourado, M. L. Barreto et al., “Sensitivity and specificity of BCG scar reading in Brazil,” International Journal of Tuberculosis and Lung Disease, vol. 5, no. 11, pp. 1067–1070, 2001. View at Google Scholar · View at Scopus
  48. S. Floyd, J. M. Ponnighaus, L. Bliss et al., “BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size,” International Journal of Tuberculosis and Lung Disease, vol. 4, no. 12, pp. 1133–1142, 2000. View at Google Scholar · View at Scopus
  49. A. Patel, F. Schofield, V. Siskind, E. Abrahams, and J. Parker, “Case-control evaluation of a school-age BCG vaccination programme in subtropical Australia,” Bulletin of the World Health Organization, vol. 69, no. 4, pp. 425–433, 1991. View at Google Scholar · View at Scopus
  50. C. Shapiro, N. Cook, D. Evans et al., “A case-control study of BCG and childhood tuberculosis in Cali, Colombia,” International Journal of Epidemiology, vol. 14, no. 3, pp. 441–446, 1985. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Brandt, J. F. Cunha, A. W. Olsen et al., “Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis,” Infection and Immunity, vol. 70, no. 2, pp. 672–678, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. G. A. W. Rook, K. Dheda, and A. Zumla, “Immune responses to tuberculosis in developing countries: implications for new vaccines,” Nature Reviews Immunology, vol. 5, no. 8, pp. 661–667, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Fallo, L. Torrado, A. Sanchez, C. Cerqueiro, L. Shadgrosky, and E. L. Lopez, “Delayed complications of Bacillus Calmette-Guerin (BCG) vaccination in HIV infected children,” in Proceedings of the Oral Abstract Sessions: the 3rd IAS Conference on HIV Pathogenesis and Treatment, Abstract no. WeOa0104, 2005.
  54. M. Tala-Heikkila, T. Nurmela, E. Tala, and J. Tuominen, “Evaluation of the BCG revaccination programme of school-children in Finland,” Bulletin of the International Union Against Tuberculosis and Lung Disease, vol. 66, no. 1, pp. 57–59, 1991. View at Google Scholar · View at Scopus
  55. W. P. Rennert, D. Kilner, M. Hale, G. Stevens, W. Stevens, and H. Crewe-Brown, “Tuberculosis in children dying with HIV-related lung disease: clinical-pathological correlations,” The International Journal of Tuberculosis and Lung Disease, vol. 6, no. 9, pp. 806–813, 2002. View at Google Scholar · View at Scopus
  56. P. van Rheenen, “The use of the paediatric tuberculosis score chart in an HIV-endemic area,” Tropical Medicine and International Health, vol. 7, no. 5, pp. 435–441, 2002. View at Publisher · View at Google Scholar · View at Scopus